Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Hexarelin vs Ipamorelin
An educational, source-based comparison of Hexarelin and Ipamorelin — how each peptide works, what it's researched for, and what to know before going deeper.
A synthetic hexapeptide and potent GHS-R agonist. Stimulates GH release more strongly than GHRP-6 and shows cardioprotective signaling in preclinical ischemia-reperfusion models, partly independent of GH.
- GH release
- Cardiac ischemia-reperfusion (preclinical)
- Left ventricular function in animal models
- • Not FDA-approved.
- • Tachyphylaxis with prolonged use.
- • Prohibited by WADA.
A selective ghrelin/GHS-R1a receptor agonist that stimulates GH release with minimal effect on cortisol, prolactin, or appetite — distinguishing it from older secretagogues like GHRP-6.
- Endogenous GH release without cortisol elevation
- Sleep quality and recovery markers
- Lean tissue retention in catabolic states
- • Generally well tolerated in research; long-term human safety data are limited.
- • Not FDA-approved.
- • Use in sport is prohibited (WADA).
Hexarelin vs Ipamorelin — Key differences
- Class: Hexarelin is classified as Growth Hormone Axis · Cardiac, while Ipamorelin is Growth Hormone Axis.
- Primary research focus: Hexarelin — gh release; Ipamorelin — endogenous gh release without cortisol elevation.
- Tag: Growth hormone vs Recovery · Sleep.